GPhA Gets Its Second Choice On Biosimilar Naming
Preemptive compromise proposing suffix on nonproprietary name offered at private meetings with FDA appear to have carried the day.
You may also be interested in...
Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.
Several fees for prescription drug, generic drug, and biosimilar applications are set to increase, although some also will drop.
The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.